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Summary. Glucocorticoids play a major role in
attenuation of the inflammatory response and they are
useful in the primary combination chemotherapy of
breast cancer, since in vitro studies have demonstrated an
antiproliferative effect in human breast cancer cells. In
contrast, it was recently shown that glucocorticoids
protect against apoptotic signals evoked by cytokines,
cAMP, tumour suppressors, and death genes in
mammary gland epithelia. Their actions are mediated by
intracellular receptor (GR) that functions as a hormone-
dependent transcription factor; however, no previous
studies have been focused on GR expression in different
pathologies of the human breast, and the possible
relationship with that of mineralocorticoid receptor
(MR) and COX-2. Also, the role of these proteins on
tumoral breast epithelial cells remains unclear.
Therefore, we examined GR, MR and COX-2 expression
by immunohistochemistry and Western blot techniques
in 142 samples of human breast obtained by total or
partial mastectomy. We found that the percentage of
positive patients presenting nuclear immunoreaction to
GR decreased with tumor development, while all
samples analyzed showed cytoplasmic immunoreactions
to MR. All positive samples to COX-2 antibody showed
cytoplasmic location, a higher immunoreaction being
observed in benign breast diseases than in carcinomatous
lesions. Thus, breast cancer progression is associated
with the accumulation of GR in the cytoplasm of
tumoral cells and the decrease of COX-2 expression.
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Introduction
The hormonal regulation of breast cancer cell
growth and survival is multifaceted and very complex
(Nass and Davidson, 1999) due to the potential for
interaction or cross talk between the different classes of
hormones, especially the ability of certain hormones to
regulate the abundance of the receptors for other
hormones (Traynor, 1995). Activated steroid receptors
affect many genes that are involved in cellular
metabolism and often affect the transcription of other
steroid receptors (Dickson and Lippman, 1988). One of
these receptors is the glucocorticoid receptor (GR)
which operates on the mechanisms of cellular
differentiation and induces apoptosis in certain cells (Lee
et al., 1988; Hulkko and Zilliacus, 2002). Taking into
account these properties, glucocorticoids have been used
in clinical oncology for more than three decades and
have a proven anti-tumour effect against lympho-
proliferative tumours (Walsh and Avashia, 2002).
Glucocorticoids play a major role in attenuation of the
inflammatory response and they are useful in the
primary combination chemotherapy of breast cancer
(Rubens et al., 1988), since in vitro studies have
demonstrated an antiproliferative effect in human breast
cancer cells (Osborne et al., 1979; Zhou et al., 1989;
Hundertmark et al., 1997). In contrast, it was recently
shown that glucocorticoids protect against apoptotic
signals evoked by cytokines, cAMP, tumour suppressors,
and death genes in mammary gland epithelia,
hepatocytes, ovarian follicular cells and fibroblasts
(Amsterdam et al., 2002).
One of the functions of glucocorticoids is to reduce
the production of prostanoids by inhibiting the
expression of COX-2 (Half et al., 2002). These proteins
catalyze the conversion of arachidonic acid to
prostaglandins, which have been detected at elevated
levels in cultured human breast cancer cells as well as in
invasive human breast cancers (Rolland et al., 1980;
Karmali et al., 1983; Schrey and Patel, 1995; Liu and
Rose, 1996). However, there are multiple contradictory
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data on elevated COX-2 (an inducible isoform of
cyclooxygenases) expression in breast neoplasia (Half et
al., 2002; Ma et al., 2004). Thus, Half and co-workers
(2002) encountered that the apparently normal breast
epithelia adjacent to the tumour site expressed COX-2 in
81% of analyzed cases; whereas Watanabe et al. (2003)
reported a low level of COX-2 expression in 50% of
normal epithelia surrounding ductal carcinoma in situ,
but in only 15% of normal epithelia surrounding
invasive disease. Moreover, it is well established that
prostaglandin production is greater in human breast
tumours than benign tumours or normal breast tissues
(Rolland et al., 1980; Boland et al., 2004).
Not only glucocorticoids but also mineralocorticoids
and its cognate receptors are involved in this regulation
of COX-2 expression (Zhang et al., 1999). Both
receptors mediate biological responses to adrenal
corticosteroids and synthetic ligands, and although many
characteristics of GR are applicable to mineralocorticoid
receptor (MR), there are significant differences between
both receptors regarding their physiological effects in the
target tissues (Bhargava and Pearce, 2004). Although the
regulation of COX-2 by mineralocorticoids was
described in rat renal medulla (Zhang et al., 2002), this
regulation has not yet been identified in human breast
cancer.
Multiple controversial data have promoted the
development of this study to evaluate, in different breast
lesions by immunohistochemistry and Western blot
analysis, the expression profile of glucocorticoid
receptor together with that of mineralocorticoid receptor
and COX-2, in order to improve our knowledge of the
relationship of these proteins in the development and
progression of breast cancer and their possible influence
in endocrine therapies responsiveness.
Materials and methods
Material
Breast samples used in this study were collected
from 142 patients (from 35 to 91 years of age) diagnosed
between 1998 and 2000 and they had a follow-up of 60
months, by the Pathology Service of the Hospital
Príncipe de Asturias of Alcalá de Henares. Primary
glandular breast lesions were classified as follows: 24
cases of benign proliferative diseases, including ductal
and lobular hyperplasia, apocrine metaplasia,
fibroadenoma, and fibrocystic changes; 38 carcinomas in
situ (CIS); 80 infiltrative carcinomas: 46 ductal (IDC)
and 34 lobular (ILC). Removal of tissues and the study
of archives samples were carried out with the consent of
patients and/or their relatives and permission of the
Ethics Committee of the Hospital. The hormonal
receptor status of infiltrative carcinomatous lesions was
determined together with the pathological diagnosis by
Príncipe de Asturias Hospital Pathology Service. None
of these patients received radiotherapy, hormonal
therapy or chemotherapy before surgery.
Each specimen was divided into two approximately
equal portions: one portion was processed for
immunohistochemistry (10% formalin fixed and paraffin
embedded), and another portion was frozen in liquid




For Western blot analysis, tissues were homogenized
in the extraction buffer (10 mM Tris-HCl, pH 7.6, 10
mM KCl, 1 mM 1,4-Ditio-L-threitol, and 0.2 M
ethylenediamine tetracetic acid, pH 8) in addition to a
cocktail of protease inhibitors (1 mM phenyl-
methanesulfonyl fluoride, 10 µg/ml of leupeptine and 1
mg/ml of aprotinine) and phosphatase inhibitors (200
mg/ml of sodium fluoride and 50 mg/ml of sodium
orthovanadate) in presence of 0.5 % Triton X-100 and
0.1% of SDS. Homogenates were centrifuged for 10 min
at 10000 rpm at 4°C. Supernatants were mixed with an
equivalent volume of SDS buffer (10% SDS in Tris/HCl
pH 8, containing 50% glycerol, 0.1 mM 2-beta-
mercaptoethanol and 0.1% bromophenol blue). Then the
mixture was denatured for 4 min at 96°C, and aliquots of
50 µ g protein were subjected to SDS-PAGE (9%
acrylamide gel for GR and 12% for MR and COX-2).
Following SDS-PAGE, proteins were transferred to
nitrocellulose membranes (0.2 mm) in the transfer buffer
(25 mM Tris-HCl, 192 mM glycine, 0.1% SDS and 20%
methanol) for 4h at 250 mA constant current. Briefly, the
blots were blocked in 5% Blotto (Santa Cruz
Biotechnology CA, USA) for 1 hour. After blocking,
blots were incubated with primary antibodies: mouse
monoclonal GR (1:200) (Novocastra Laboratories LTD,
UK; Santa Cruz), mouse monoclonal MR (1:4000)
(Affinity Bioreagents Golden, CO; Santa Cruz), and
rabbit polyclonal COX-2 (1:1000) (Santa Cruz). All of
them diluted in blocking solution 1:9 overnight at room
temperature. After extensive washing with TBS/Tween
20, the membranes were incubated with biotinylated
immunoglobulins diluted in blocking solution 1:9, rabbit
anti-mouse for GR and MR, or swine anti-rabbit for
COX-2 (Dako, Barcelona, Spain) at 1:2000 and after an
extensive wash, the sheets were incubated with
streptavidin-peroxidase (Zymed Laboratories Inc. South
San Francisco, CA, US) at 1:10000 dilution in the same
blocking solution 1:9. Finally, the membranes were
developed with an enhanced chemiluminescence (ECL)
kit, following the procedure described by the
manufacturer (Amersham, Buckinghamshire, UK). Blots
were stripped and re-probed with an anti-human ß-actin
monoclonal antibody (Amersham) to control for equal
sample loading.
Immunohistochemistry
Sections, 5-µm-thick, were deparaffinised in xylene
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and rehydrated using graded ethanol concentrations.
Following deparaffination, sections were hydrated and
those destined to be labelled using the streptavidin-
biotin-peroxidase method were incubated with 3%
hydrogen peroxide for 20 min at room temperature to
inactivate endogenous peroxidase. Antigen retrieval was
achieved by the pressure cooking method for 30 sec. in
0.1 M citrate buffer (pH 6). After rinsing in Tris-buffered
saline (TBS), the slides were incubated with blocking
solution (3% normal donkey serum (NDS) plus 0.05%
Triton in TBS for GR, and 20% NDS plus 5% bovine
serum albumin (BSA) in TBS for MR and COX-2) for
45 min to prevent non-specific binding of the first
antibody. Afterwards, the sections were incubated
overnight at room temperature, with the primary
antibodies (GR 1:20, MR 1:400, COX-2 1:150) in their
respective blocking solution diluted 1:9.
Then, the sections were washed in TBS and
incubated for 1 hour with either rabbit anti-mouse (for
GR and MR), or swine anti-rabbit (for COX-2)
biotinylated immunoglobulins (Dako), diluted 1:500 in
blocking solution 1:9. After an extensive wash in TBS,
the sections were incubated with the streptavidin-
peroxidase (Zymed) for GR and COX-2 antibodies and
for MR with the streptavidin-alkaline phosphatase
(Zymed) complexes for 45 min at room temperature.
The peroxidase and alkaline phosphatase activities were
detected using the glucose oxidase-DAB-nickel
intensification method and the Zymed’s AP-red solution
respectively. DAB stained sections were dehydrated,
cleared in xylene, and mounted in DePex (Probus,
Badalona, Spain). AP-red stained samples were
counterstained with haematoxylin and coverslipped
using AquaTex (Merck, NJ, USA).
To assess the specificity of immunoreactions,
negative and positive controls were used. As negative
controls, sections of breast samples processed identically
were incubated using the antibody preabsorbed with
corresponding blocking peptide (purchased from Santa
Cruz), or omitting the primary antibody. As positive
controls, sections of rat adrenal gland and kidney were
processed with the same antibody. 
The staining intensity of GR, MR and COX-2 was
classified into two categories: 0, negative or staining was
observed in less than 10% of the cells; 1, staining was
detected in more than 10% of the cells. In contrast to
nuclear staining of GR and MR, the staining pattern of
the extranuclear expression for these proteins was
observed in two types: diffuse staining and spotted
staining in the cytoplasm according to the following
criteria: score 0, no staining at all; 1, a faint/barely
perceptible staining; 2 and 3, a weak to moderate
staining or a strong staining was observed in more than
10% of the tumour cells. Only scores 2 and 3 were
assessed as positive expression. The assessment of the
grade of staining was performed in a blinded way always
by the same experienced investigators (I.C., M.I.A.).
Statistical analysis
Data retrieval and analysis were made using a
personal computer and a statistical program (SPSS 12.0).
To perform a differential analysis of the positive patients
for GR, MR and COX-2 among the different lesions of
the breast, Dunn's Multiple Comparison Test was used.
In infiltrative carcinomas, univariate analysis comparing
categorical variables (GR, MR and COX-2 expression
and clinicopathological data -patient age, tumor grade,
axillary lymph node status, estrogen and progesterone
receptor status, histological type, free-time disease-) was
performed using chi-square tests. We test for the
presence of a linear trend when there were more than
two categories of staining using the Mantel-Haenszel
chi-square statistic. Continuous variables were compared
using the Mann-Whitney test. For all these tests we
computed p-values using an exact method due to small
sample sizes. This analysis was completed with multiple
regression analyses (Durbin-Watson statistic) to
evaluate, in these infiltrative carcinomas, the possible
dependence between GR expression and the other
variables analyzed. All tests were performed in the two




To check the antibodies specificity, in some samples
from each breast lesion, Western blot analysis was
performed and results are shown in Figure 1. For each
antibody, only a single band at the corresponding
molecular weight was found: 94 kDa for GR, 116 kDa
for MR, and 70 kDa for COX-2.
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Fig. 1. GR, MR and COX-2 Western blot
analysis. 1: benign breast diseases (BBDs), 2:
carcinomas in situ (CIS), 3: infiltrative ductal
carcinomas (IDC), 4: infi l trative lobular
carcinomas (ILC). Each blot is representative of
its respective group. After stripping,
immunoreactivity with an anti-ß-actin antibody
was used as loading control (actin, bottom
panel).
Immunohistochemical characterization of samples of
benign lesions
The percentage of positive samples for GR, MR and
COX-2 immunostaining is indicated in Figure 2. No
background immunoreaction to GR, MR and COX-2
was observed in any of the negative controls (Fig. 3,
inset). As expected, samples of rat adrenal gland and
kidney showed an intense staining for these antibodies. 
In the benign lesions examined, GR
immunolabelling was observed in the nuclei of ductal
and acinar cells (Fig. 3A). Stromal cell nuclei were
immunoreactive to GR and a strong immunoreactivity
was also observed in the nuclei of myoepithelial cells
surrounding breast ducts. This immunostaining pattern
was observed in 100% of samples studied.
All benign breast lesions showed a very strong
immunoreaction to MR but uniformly distributed in the
cytoplasmic compartment and in some cells around the
nucleus (Fig. 3B). Also, a strong immunoreactivity in
the smooth muscle of the tunica media of blood vessels
and in the stromal cells was observed. COX-2 enzyme
labelling was detected in 20 of 24 samples analyzed
(83.4%) and this immunostaining was not uniformly
distributed and only observed in some cells and
preferentially in ductal formations and located in the
basal and apical cytoplasm (Fig. 3C). No
immunoreactivity was observed in stromal cells or in
vasculature around normal breast ducts.
Immunohistochemical characterization of carcinomatous
samples
In samples that presented ductal and lobular
carcinoma in situ, a positive reaction to GR, MR and
COX-2 antibodies was observed in the whole tumoral
architecture (Fig. 3D, E, and F respectively), regardless
of whether it corresponded to a solid structure, a
cribiform pattern or a papillary pattern. The percentage
of positive samples for GR and COX-2 was lower in
these carcinomas than in benign breast diseases, while
the MR presented the same pattern of expression as in
benign lesions.
In samples of infiltrating ductal carcinoma, solid
clusters of tumour tissue were observed. In these
clusters, the percentage of immunoreaction observed for
GR was lower than that observed in benign breast
lesions and carcinomas in situ, though its immuno-
expression was located in the nuclei, as well as in the
cytoplasm (Fig. 3G). The location and percentage of
immunostaining of MR was similar to that encountered
in the other lesions analysed (Fig. 3H). COX-2
immunoreaction was located in the cytoplasm of most
neoplastic cells, but the percentage of positive samples
was reduced (Fig. 3I).
Samples of infiltrating lobular carcinoma which
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Fig. 2. Percentage of positive samples for GR, MR and COX-2. BBDs: benign breast lesions. CIS: carcinomas in situ. IDC: infiltrative ductal
carcinomas. ILC: infiltrative lobular carcinomas. N: nucleus. C: cytoplasm.
Fig. 3. For all micrographs: bar, 20 µm. A. Nuclear immunostaining of GR in fibroadenoma. Inset: Negative control section was obtained when it was
incubated with antibody pre-absorbed with blocking peptide. B. Cytoplasmic immunoreaction to MR in lobular hyperplasia. C. COX-2 was located in the
cytoplasmic compartment of hyperplasic lesions in both basal and apical cytoplasm. D. CIS showing nuclear immunoreaction to GR. E. Numerous and
large macrophages (*) can be observed around a ductal in situ formation positive to MR. F. In CIS, some cells showed an intense cytoplasmic
immunoreaction to COX-2, whereas other cells were negative. G. Infiltrative ductal carcinomas showing cytoplasmic immunostaining to GR. H. Strong
cytoplasmic immunoreaction to MR in infiltrative ductal carcinoma. I. Ductal infiltrative carcinoma presents cytoplasmic immunostaining to COX-2. J.
Cytoplasmic localization of GR in infiltrative lobular carcinoma. K. Sample presenting ILC showing a strong MR immunostaining, mainly located around
the nuclei of neoplastic cells. L. In infiltrative lobular carcinomas, an intense immunoreaction to COX-2 can be observed in the cytoplasm.
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were characterized by the presence of small cells
diffusely invading the stroma showed reactivity to GR in
both the nuclei and the cytoplasm of tumoral cells (Fig.
3J), though the number of positive samples was reduced.
Stromal cell nuclei were also immunoreactive.
Immunoreaction to MR and COX-2 was similar to that
observed in infiltrative ductal carcinomas (Fig. 3K, L).
Statistical analysis
A Dunn’s Multiple Comparison Test carried out the
significance of differences in the expression pattern of
each protein studied between the different patient
groups. The results of GR and MR values differed
significantly between benign breast lesions and
infiltrative carcinomas (p<0.001 and p<0.01
respectively). With the tumoral progression, no
differences in the COX-2 expression pattern were
encountered. 
The Fisher’s exact test or Chi-square test between
different clinicopathological data, such as the age of
patients, the tumour stage, the lymph node status,
estrogen and progesterone receptors status, free-time
disease and the expression of GR, MR and COX-2
showed that only the cytoplasmic expression of GR
presented a direct, significant statistical association with
the patients’ age (p=0.0007) and with the free-time
disease (p=0.013) (Table 1). To check whether the
association of GR with free-time disease is secondary to
the association with patients’ age, we performed an
analysis of variance by ranks (Kruskal-Wallis test)
observing that each variable differed from one of the
others. The multiple regression analysis showed a
marked direct association between the GR and ER-α
expression (p=0.0079).
Discussion
Adrenal corticosteroids, glucocorticoids and
mineralocorticoids play important physiological roles in
humans and their actions are mediated by intracellular
receptor molecules (GR and MR) that function as
hormone-dependent transcription factors. Ligand-
activated receptors modulate the transcription rates of
responsive genes by either interacting with responsive
elements in the promoters of these genes or influencing
the activities of other transcription factors, via protein-
protein interactions (Kino and Chrousos, 2004). The
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Table 1. Association of GR immunoexpression with expression of MR, COX-2 and several clinicopathological factors in breast infiltrative carcinomas.
Fisher’s exact test (p<0.05).
n Negatives Nucleus p value Cytoplasm p value
Age (years)
≤ 50 20 10 10 0
>50 60 16 18 1 26 0.0007
TNM
T1 38 8 16 14
T2 34 18 10 6
T3 4 0 2 2
T4 4 0 0 0.208 4 0.512
Nodal status
- 36 6 18 12
+ 44 20 10 0.003 14 0.144
ER
- 16 8 4 4
+ 64 18 24 0.196 22 0.323
PR
- 18 4 8 6
+ 62 22 20 0.331 20 0.726
Histological type
Ductal 56 18 20 18
Lobular 24 8 8 1 8 1.235
FTD (months)
5-20 10 0 4 6
20-30 20 10 6 4
>30 50 16 18 0.080 16 0.013
MR
- 0 0 0 0
+ 80 26 28 - 26 -
COX-2
- 24 8 4 12
+ 56 18 24 0.196 14 0.392
FTD: free-time disease.
specificity of the glucocorticoid receptors transcriptional
activity varies widely between cell types, accounting for
the diverse -and sometimes opposite- physiological
effects of glucocorticoids in different tissues. Thus,
glucocorticoids have been shown to promote apoptosis
in lymphocytes (Wyllie, 1980; Schwartzman and
Cidlowski, 1994), whereas in rat hepatoma epithelial
cells (Evans-Storms and Cidlowski, 1994) and human
mammary epithelial cells (Moran et al., 2000) are
protected from apoptosis after GR activation and this
activation is realized by the MKP-1 up-regulation (Wu et
al., 2005). We have observed that, in the carcinoma
development, the nuclear GR expression is lost in a high
number of samples; this loss might be explained by the
receptor nucleocytoplasmic shuttling (Madam and
DeFranco, 1993), since unliganded glucocorticoid
receptors are usually located within the cytoplasmic
compartment (Qi et al., 1989) and also, in patients with
breast cancer, a flattened cortisol rhythm occurs
(Sephton et al., 2000). Our findings are in accordance
with those reported by Ioannidis et al. (1982) who
detected GR expression in all manignant breast tumours
and fibrocystic disease was negative. However, Lien et
al. (2006) have observed a strong expression of GR in
metaplastic carcinomas and malignant phyllodes
tumours, and non-metaplastic carcinomas were only
positive in 3.9% of cases. These discrepancies are
unlikely to be due to differences in the methodology,
since a careful comparison of the procedures used by
these authors revealed no important differences in the
procedure for immunolabelling. A different degree of
immunoreactivity might be due to the antibody used, but
this would only explain the absence of cytoplasmic GR
since it is particularly significant that Lien et al (2006)
failed to detect the well-known presence of unliganded
GR in the cytoplasm (Qi et al., 1989), a fact that
suggests the antibody might only recognize DNA-bound
GR receptor. On the other hand, we have studied
primary, non-treated tumours, whereas we have no
indication of whether the samples from the study of Lien
et al (2006) came from treated or non-treated patients. It
is conceivable that cancer therapy may modify the
expression profile of GR. Finally, conflicting reports
regarding the expression pattern of a given protein in
cancer tissues are frequently published. Clearly, more
studies are needed to elucidate the degree of expression
of GR in pathological and non-pathological breast
tissues.
Our results showed that, in infiltrative lobular
carcinomas, GR and ER-α are dependent on each other.
In several physiological and pathophysiologic processes
estrogen action is opposed to glucocorticoids. Thus,
numerous breast tumour cell lines have been
demonstrated to have both ER and GR (Ewing et al.,
1989), observing that estrogen promotes growth,
whereas glucocorticoids inhibit it (Zhou et al., 1989).
Therefore, there are potential interactions for ER/GR at
the level of transcription (Uht et al., 1997). Also, it has
been reported that estrogen causes a significant down-
regulation of GR expression in breast cancer cells
leading to a substantial suppression of GR-mediated
transcriptional activity (Krishnan et al., 2001).
Although we have not encountered any correlation
between PR status and GR expression in carcinoma
samples, several studies have reported the progesterone-
like effects of glucocorticoids and mineralocorticoids
(Schneider et al., 1999; Jiang et al., 2002) and both
molecules cross-talk with PR to induce growth inhibition
and focal adhesion in breast cancer cells (Leo et al.,
2002). Moreover, in our study, no relationship between
MR and GR was observed even though van Steensel et
al. (1996) have shown that both receptors colocalize in
specific nuclear domains and form heterodimeric
complexes resulting in a pattern of gene expression
different from that of either receptor alone. However,
there are no data available about the biological role of
the mineralocorticoid receptor in the process of
apoptosis. Sasano et al. (1997) localized this receptor in
breast ductal epithelial cells, and correlated its presence
to the ductal differentiation of breast carcinomas. We
detected a strong immunoreaction to MR in all breast
lesions and this widely cytoplasmic distribution could be
related to the possibility that the MR compensate the
loss of GR expression as has been observed in regulating
the transcription of milk protein genes among the
different steps of mammary gland development
(Kingsley-Kallesen et al., 2002).
One of the multiple functions of both mineralo-
corticoids and glucocorticoids is the regulation of COX-
2 expression (Zhang et al., 1999). However, no studies
of this regulation have been performed in human breast
lesions. Such studies would be very interesting because
non-steroideal anti-inflammatory drugs inhibit COX
enzymes and are potent chemopreventive agents against
some mammary models (Half et al., 2002). Thus, we
have observed that the patients who seem to be the most
influenced by all of these proteins are those who present
benign breast disease, since a high number of patients
were positive for these proteins. This observation was
surprising considering that previous studies showed
overexpression of COX-2 in breast malignant tumours
(Half et al., 2002; Ristimäki et al., 2002; Shim et al.,
2003; Boland et al., 2004; Ranger et al., 2004) and that
this expression is associated with angiogenesis and
lymph node metastasis (Costa et al., 2002), tumour size
or grade (Zhang et al., 1999), although other studies
have not encountered any association (Kelly et al., 2003;
Ranger et al., 2003); however, these studies have
exclusively been focused on COX-2 expression in breast
cancer lesions. Half et al. (2002) have recently
demonstrated that ductal carcinomas in situ (DCIS)
adjacent to invasive cancer expressed higher COX-2
levels than the invasive component, suggesting that
COX-2 expression could be an early event in breast
carcinogenesis. Our study, extended to the analysis of
benign breast diseases, revealed that overexpression of
this enzyme is higher in these lesions than in breast
cancer considering the percentage of samples, although
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in these immunolabelled samples the number of positive
cells was decreased. Together with this expression
pattern, the presence of nuclear GR in these lesions
suggests that the chemopreventive use of COX-2
inhibitors may have profound effects on breast cancer
incidence. However, further specific studies should be
performed to test this hypothesis. 
The percentage of nuclear immunoreaction to GR in
benign breast lesions was related to the highest
percentage of COX-2 immunostaining. Breast cancer
progression is associated with high accumulation of GR
in the cytoplasm and lower percentage of positive
samples for COX-2. This fall in immunostaining was not
observed for MR, suggesting that when this receptor is
activated by its corresponding ligand, it could substitute
the role of GR as an inhibitor of COX-2 in the treatment
of breast cancer.
In summary, our results suggest that breast cancer
progression is associated with the accumulation of GR in
the cytoplasm of tumoral cells and the decrease of COX-
2 expression. Therefore, it could be interesting to assess
the role of GR as a new marker of neoplastic
transformation in the human breast.
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